5-MeO-DMT

5-MeO-DMT is a psychedelic tryptamine that appears to be an endogenous drug. It can be found in many plants and is also produced by the Bufo alvarius toad.

The drug has been used for centuries in South America and the Caribbean. To this day, it is used by indigenous groups in the form of intranasal snuffs.

It can produce fully dissociative psychedelic experiences, similar to DMT. However, 5-MeO-DMT is far less visual with its effects and seems more likely to cause terror/anxiety responses.

5-MeO-DMT = 5-MeO; 5-methoxy-N,N-dimethyltryptamine; N,N-Dimethyl-5-methoxytryptamine; 5-Methoxy-N,N-dimethyltryptamine; Methoxybufotenin

PubChem: 1832

Molecular formula: C13H18N2O

Molecular weight: 218.3 g/mol

IUPAC: 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine

Dose

Oral (tentative)

Light: 10 – 15 mg

Common: 15 – 40 mg

Strong: 40+ mg

With MAOI: 10 – 20 mg

Inhalation

Light: 2 – 5 mg

Common: 5 – 10 mg

Strong: 10 – 15 mg

Intranasal

Light: 5 – 8 mg

Common: 8 – 15 mg

Strong: 15+ mg

Sublingual

Light: 5 – 8 mg

Common: 8 – 15 mg

Strong: 15+ mg

Timeline

Oral (tentative)

Total: 1 – 2 hours

Onset: 00:10 – 00:30

Inhalation

Total: 5 – 20 minutes

Onset: Under 1 minute

Intranasal

Total: 1 – 1.5 hours

Onset: 00:02 – 00:05

Sublingual

Total: 45 min – 1 hour

Onset: 00:10 – 00:15

Experience Reports

Erowid

Test Results

References

(2014) The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.

(2012) A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.

(2012) Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.

(2011) Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions

(2011) Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.

(2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.

(2006) The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.

(2006) A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation.

(2005) A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation.

(2004) Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances.

(2001) Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.

(1997) Suppressive Effect of Mitragynine on the 5-Methoxy-N,N-dimethyltryptamine-Induced Head-Twitch Response in Mice

(1987) In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat.

(1987) Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine.

(1985) Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat.

(1976) Biogenesis of 5-methoxy-N,N-dimethyltryptamine in human pineal gland

(1972) Effects of 5-methoxy-N,N-dimethyltryptamine on central monoamine neurons

(1972) Biosynthesis and turnover of N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in Phalaris tuberosa

(1968) Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines

(1959) Indole Alkaloids of Acer saccharinum (the Silver Maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis